Navigation Links
AbbVie to Present at Jefferies 2013 Healthcare Conference
Date:11/14/2013

NORTH CHICAGO, Ill., Nov. 14, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2013 Healthcare Conference on Thursday, Nov. 21, 2013. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 10:40 a.m. Greenwich Meantime (4:40 a.m. Central time).

A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web site at www.abbvieinvestor.com.  An archived edition of the session will be available later that day.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.


'/>"/>
SOURCE AbbVie Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AbbVie to Present at Credit Suisse 2013 Healthcare Conference
2. AbbVie to Present at Morgan Stanley Global Healthcare Conference
3. Vote to Help Award a $21,000 AbbVie CF Scholarship to Two Inspirational Students with Cystic Fibrosis Pursuing their Goals of Higher Education
4. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
5. StockCall Scrutinizes Pfizer, Merck & Co., Johnson & Johnson, and AbbVie
6. AbbVie to Present at Cowen and Company 33rd Annual Health Care Conference
7. AbbVie Declares Dividend and Announces Share Repurchase Program
8. Caris Life Sciences Presents Key Biomarker Data at 2013 Association for Molecular Pathology (AMP) Annual Meeting
9. Ultra-Orphan Drug Specialists Represent Poor Value for Money as M&A Targets
10. PAREXEL International to Present at Jefferies Global Healthcare Conference
11. CONRAD presents new technology combining contraception, HIV and herpes simplex virus-2 prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Theravalues Corporation est fier d,annoncer le lancement ... salon Hi Europe 2014 (du 2 au 4 décembre ... Curcumine la plus biodisponible actuellement sur le marché, ... ingrédients approuvés par les règlements européens. ... la racine de curcuma ( Curcuma longa ) ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... Ltd., a,privately-held drug development company with its headquarters ... new Phase IIa clinical testing of,ProtoCure(TM) emulsion cream, ... vehicle-controlled study is designed to,evaluate the tolerability, pharmacokinetics, ... of 18 subjects with mild to moderate plaque ...
... through non core divestitures - , - Caliper signs ... , - Non-cash restructuring and goodwill impairment charge ... Caliper Life Sciences, Inc. (Nasdaq: CALP ), today ... 2008. Fourth quarter revenues were $36.7 million, a decline ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company,) (NYSE: ... pharmaceuticals and manufacturer of the patented,anti-cancer biotech product Endu ... and fiscal year ended December 31, 2008. , , ... revenue increased to RMB 466.9 million (US$68.4 million) for ...
Cached Biology Technology:BioCis Pharma Starts Phase IIa Trial in Psoriasis 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 3Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 4Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 5Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 6Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 7Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 8Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 9Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 10Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 11Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 12Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 13Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 14Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 12Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 13
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... - The meters-long, carnivorous "shrimp" from hell that once ruled the ... a real softy, it turns out. A new 3-D modeling of ... parts were not hard like teeth, but flexible, shows that the ... of trilobites and other such creatures of the early seas. ...
... Environmental Pollution " details successful experiments at the ... the abiotic (non-biological) transformation and absorption of four ... these estrogen hormones by more than 80 percent ... since it could point to inexpensive treatment technologies ...
... courses of antibiotics can leave normal gut bacteria harbouring ... treatment, say scientists writing in the latest issue of ... researchers believe that this reservoir increases the chances of ... survival and suggesting that the long-term effects of antibiotic ...
Cached Biology News:Earth's first great predator wasn't 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 3Antibiotics have long-term impacts on gut flora 2
Lingo-1 (K-13)...
HIF-1 beta (ARNT1) Purified Anti-Mouse, Anti-Rat, Anti-Human clone 29, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: